In 2020, it was estimated that around 10.6 percent of the world population had chronic obstructive pulmonary disease (COPD). Over the coming decades, the prevalence of COPD is expected to decrease. This statistic shows the prevalence of COPD worldwide in 2020 and projections to 2050.

A dataset providing GP recorded chronic obstructive pulmonary disease rates.

Chronic Obstructive Pulmonary Disease (COPD) is a serious long-term lung disease in which the flow of air into the lungs is gradually reduced by inflammation of the air passages and damage to the lung tissue. Chronic Bronchitis and emphysema are common types of COPD.

Chronic Obstructive Pulmonary Disease (COPD) is the fifth biggest killer disease in the UK, killing approximately 25,000 people a year in England.

Further information

For more information on public health, please visit: http://www.leeds.gov.uk/phrc/Pages/default.aspx

In 2023, around two percent of Hispanics in the United States had chronic obstructive pulmonary disease (COPD), compared to 4.4 percent of white, non-Hispanics. This statistic shows the percentage of adults in the U.S. with COPD in 2023, by race and ethnicity.

Chronic Obstructive Pulmonary Disease (COPD) prevalence data is from the Canadian Chronic Disease Surveillance System (CCDSS). Chronic Obstructive Pulmonary Disease (COPD) crude prevalence in Nova Scotia. Includes the following data fields: Management Zone, Sex, Age Group, Population, Chronic disease 2 Count, Crude Prevalence Rate %

In 2021, around **** percent of U.S. adults who were current smokers had COPD, compared to only *** percent of those who had never smoked. This statistic shows the percentage of adults in the U.S. with chronic obstructive pulmonary disease (COPD) in 2011 and 2021, by smoking status.

Utilising a regression analysis we created a correlation matrix utilising a number of demographic indicators from the Local Insight platform. This application is showing the distribution of the datasets that were found to have the strongest relationships, with the base comparison dataset of COPD prevalence. This app contains the following datasets: prevalence of peripheral arterial disease, prevalence of epilepsy, people over the age of 25 to 34 with Level 2 qualifications, proportion of the population with no passport, proportion of households comprised one cohabiting couple with dependent children, proportion of people with skilled trades occupations, proportion of people working in the construction industry, proportion of people in social grade (N-SEC) 5 lower supervisory and technical occupations, proportion of the population born in England and MSOAs identified as hard-pressed living.

Chronic Obstructive Pulmonary Disease (COPD) Support Services Market Outlook

The global Chronic Obstructive Pulmonary Disease (COPD) Support Services market size was valued at approximately $15 billion in 2023 and is projected to reach around $24 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.5% during the forecast period. A significant growth factor for this market is the increasing prevalence of COPD worldwide, driven by factors such as aging populations, high smoking rates, and rising exposure to environmental pollutants.

One of the primary growth drivers for the COPD Support Services market is the aging global population. As people age, the likelihood of developing chronic respiratory diseases like COPD increases, necessitating a comprehensive range of support services. Moreover, the World Health Organization estimates that the proportion of the global population aged 60 years and older will nearly double from 12% to 22% between 2015 and 2050. This demographic shift underscores the need for robust COPD support services to manage the growing patient population effectively.

Another significant factor contributing to market growth is the increasing awareness and diagnosis of COPD. Improved screening and diagnostic technologies have made it easier for healthcare providers to identify COPD at earlier stages, leading to timely intervention and management. Public health campaigns and educational initiatives have also played a crucial role in raising awareness about COPD, its risk factors, and the importance of early diagnosis and management. These efforts are likely to continue driving demand for a variety of support services tailored to COPD patients.

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes breathing difficulties and is characterized by long-term respiratory symptoms and airflow limitation. It encompasses conditions such as emphysema and chronic bronchitis, which lead to the obstruction of airflow from the lungs. The disease is primarily caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. In addition to smoking, factors such as air pollution, occupational dust, and genetic predispositions can contribute to the development of COPD. Understanding these underlying causes is crucial for developing effective prevention and management strategies. As the disease progresses, patients may experience worsening symptoms, including increased breathlessness, frequent coughing, and a decline in physical activity levels. Early diagnosis and intervention are essential in managing COPD and improving patients' quality of life.

The rising burden of environmental pollutants and occupational hazards also contributes to the increasing prevalence of COPD, thereby boosting the demand for COPD support services. Industrial emissions, vehicular pollution, and indoor air pollutants are significant contributors to respiratory diseases, including COPD. Additionally, certain occupations that expose workers to dust, chemicals, and fumes are associated with a higher risk of developing COPD. Consequently, the need for specialized services to manage and mitigate the impact of these factors is becoming increasingly important.

Regionally, North America and Europe dominate the COPD support services market due to well-established healthcare infrastructure, high prevalence of the disease, and substantial investment in healthcare services and technologies. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period. This growth can be attributed to increasing healthcare expenditure, improving healthcare infrastructure, and a rising prevalence of COPD due to factors such as air pollution and smoking rates. The Middle East & Africa and Latin America regions also present significant growth opportunities due to their developing healthcare sectors and increasing awareness about COPD management.

Pulmonary Rehabilitation Analysis

Pulmonary rehabilitation services are a cornerstone of COPD management, focusing on improving the overall physical and emotional well-being of patients. These programs typically include exercise training, nutritional advice, education on the disease, and behavioral counseling. The integration of multidisciplinary teams, including physiotherapists, dietitians, and psychologists, ensures a holistic approach to patient care. The demand for pulmonary rehabilitation services is expected

Chronic Obstructive Pulmonary Disorder Market Outlook

The global Chronic Obstructive Pulmonary Disorder (COPD) market size was valued at USD 15.3 billion in 2023 and is projected to reach approximately USD 24.8 billion by 2032, growing at a CAGR of 5.5% during the forecast period. The growth of the COPD market is primarily driven by the increasing prevalence of respiratory diseases, rising geriatric population, and advancements in medical technologies.

The rising prevalence of COPD globally is one of the major growth factors. Factors contributing to the increasing incidence of COPD include rising air pollution, smoking, and occupational exposure to dust and chemicals. The World Health Organization (WHO) estimates that COPD will become the third leading cause of death worldwide by 2030, underscoring the urgent need for effective treatments and management strategies. Additionally, the aging population is more susceptible to chronic respiratory diseases, which further propels the market growth.

Technological advancements in medical devices and treatments are also fostering market growth. The development of advanced inhalers and nebulizers, which offer better drug delivery and patient compliance, is a significant contributor. Innovations in bronchodilators, phosphodiesterase-4 inhibitors, and combination therapies have enhanced the treatment efficacy for COPD patients. Pharmaceutical companies are investing heavily in research and development to bring novel and more effective therapeutics to the market.

Government initiatives and funding aimed at combating COPD and other chronic respiratory diseases are another crucial driving force. Numerous healthcare policies and programs are focused on early diagnosis, comprehensive management plans, and increasing public awareness about COPD. These initiatives not only improve patient outcomes but also create substantial opportunities for market players to expand their product portfolios and reach.

The role of Asthma and COPD Devices in managing chronic respiratory conditions cannot be overstated. These devices, including inhalers and nebulizers, are essential tools in delivering medication directly to the lungs, ensuring rapid relief and improved patient outcomes. With advancements in technology, newer devices are becoming more user-friendly, enhancing patient compliance and treatment efficacy. The development of smart inhalers, which offer real-time data tracking and reminders, is a testament to the ongoing innovation in this field. As the prevalence of respiratory diseases continues to rise, the demand for effective and efficient Asthma and COPD Devices is expected to grow, driving further advancements and market expansion.

Regionally, North America holds the largest share in the COPD market, owing to the high prevalence of COPD, advanced healthcare infrastructure, and significant investment in research and development. Europe follows closely, with countries like Germany, the UK, and France contributing majorly due to their robust healthcare systems and increasing awareness about chronic respiratory diseases. The Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by rising pollution levels, increasing smoking rates, and improving healthcare infrastructure.

Drug Class Analysis

Bronchodilators are the cornerstone of COPD treatment, aimed at relaxing the muscles around the airways to make breathing easier. These medications can be short-acting or long-acting, providing relief from symptoms for varying durations. The market for bronchodilators is substantial due to their primary role in managing COPD symptoms. The continuous need for effective symptom relief and the development of novel bronchodilators are projected to drive this segment's growth.

Phosphodiesterase-4 inhibitors represent a newer class of drugs used in the treatment of COPD, particularly for patients with severe symptoms and frequent exacerbations. These drugs work by reducing inflammation in the airways. Although currently a smaller segment compared to bronchodilators, the market for phosphodiesterase-4 inhibitors is expected to grow rapidly due to ongoing research and development efforts aimed at enhancing their efficacy and reducing side effects.

Steroids are another critical component in the COPD treatment regimen, particularly during acute exacerbations. Inhaled corticosteroids are commonly used to r

It is predicted that in 2050 around 15 percent of the population in Sub-Saharan Africa will have chronic obstructive pulmonary disease (COPD), making it the region with the highest prevalence of COPD worldwide. This statistic illustrates the projected prevalence rate of COPD worldwide in 2050, by region.

This dataset presents information on age-standardized incidence rates of chronic obstructive pulmonary disease (COPD) for Alberta, and select geographies , expressed as per 100,000 population.

This dataset presents information on age-sex specific incidence rates of chronic obstructive pulmonary disease (COPD) for Alberta, expressed as per 100,000 population.

Death rate has been age-adjusted by the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Chronic obstructive pulmonary disease (COPD) refers to a group of diseases, including emphysema and chronic bronchitis, that create airflow blockages in the lungs. Exposure to tobacco smoke is an important risk factor for COPD. Cities and communities can take an active role in curbing tobacco use and reducing COPD by adopting policies to regulate tobacco retail; reducing exposure to secondhand smoke in outdoor public spaces, such as parks, restaurants, or in multi-unit housing; and improving access to tobacco cessation programs and other preventive services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

Chronic obstructive pulmonary disease (COPD) causes a high disease burden among the elderly worldwide. In Taiwan, the long-term temporal trend of COPD mortality is declining, but the geographical disparity of the disease is not yet known. Nationwide COPD age-adjusted mortality at the township level during 1999–2007 is used for elucidating the geographical distribution of the disease. With an ordinary least squares (OLS) model and geographically weighted regression (GWR), the ecologic risk factors such as smoking rate, area deprivation index, tuberculosis exposure, percentage of aborigines, density of health care facilities, air pollution and altitude are all considered in both models to evaluate their effects on mortality. Global and local Moran’s I are used for examining their spatial autocorrelation and identifying clusters. During the study period, the COPD age-adjusted mortality rates in males declined from 26.83 to 19.67 per 100,000 population, and those in females declined from 8.98 to 5.70 per 100,000 population. Overall, males’ COPD mortality rate was around three times higher than females’. In the results of GWR, the median coefficients of smoking rate, the percentage of aborigines, PM10 and the altitude are positively correlated with COPD mortality in males and females. The median value of density of health care facilities is negatively correlated with COPD mortality. The overall adjusted R-squares are about 20% higher in the GWR model than in the OLS model. The local Moran’s I of the GWR’s residuals reflected the consistent high-high cluster in southern Taiwan. The findings indicate that geographical disparities in COPD mortality exist. Future epidemiological investigation is required to understand the specific risk factors within the clustering areas.

Chronic obstructive pulmonary disease (COPD) is a lung disease characterised by obstruction in the airflow which interferes with the normal breathing pattern. The World Health Organisation (WHO) announced COPD will be the third common cause for death by 2020. The objective of study is to assess the level of prevalence and awareness of risk factors of COPD and its symptoms among college students. An online survey among 270 college going student age between 18 to 28 year was done across the country. Questionnaire assessed the smoking rate, risk factors, symptoms, and awareness among college student related to COPD. Total of 270 individuals participated in the study. Out of total 52% are male and 47.9% female. Out of total 64.1% participant smoke and 35.9% don’t smoke. 36.3% participant said that another person frequently smokes around. - The study shows that there are no relevant symptoms shown in college student, but the population is mainly affected by air pollution and passive smoking. There is not much awareness regarding COPD.

Key statistics on copd prevalence, societal costs, and health indicators for Germany.

Mortality from bronchitis and emphysema and other chronic obstructive pulmonary disease (ICD-10 J40-J44 equivalent to ICD-9 490-492, 496) To reduce deaths from bronchitis, emphysema and other chronic obstructive pulmonary disease. Legacy unique identifier: P00179

In 2022, around ** percent of adults aged 18 years and older in West Virginia had chronic obstructive pulmonary disease (COPD), the highest share of any U.S. state. This statistic shows the prevalence of COPD among U.S. adults in 2022, by state.

This dataset presents information on age-sex specific prevalence of chronic obstructive pulmonary disease (COPD) for Alberta, Alberta Health Services (AHS) continuum zones, and former health regions, expressed as a percentage.

Key statistics on copd prevalence, societal costs, and health indicators for Austria.

All values are expressed as Mean (SD). BMI: body mass index, FEV1: forced expiratory volume in 1 second, FEV1/FVC ratio: Forced expiratory volume in 1 second (FEV1) expressed as a percentage of Forced vital capacity (FVC), GOLD: global initiative for obstructive lung disease stage, MMSE: Mini Mental State Examination.